and no transmissible antibiotic resistance was detected. It has inherent acid resistance and is able to tolerate pH2 with a survival rate of 20%, increasing to 76% at pH3. It is able to metabolise a range of carbohydrates, including lactose, glucose, sucrose, fructose, mannose, ribose, raffinose and N acetyl glucosamine.

**Conclusion** Our candidate probiotic, *S thermophilus* NCIMB 41856 has properties that would enable it to survive in and colonise the human intestine. It can survive gastric levels of acidity, utilise a range of carbohydrates present in the intestine, and is able to bind to epithelial cells. It is also able to prevent the binding of potential pathogens. Furthermore, it does not possess undesirable antibiotic resistance or produce harmful metabolic products. These features indicate that it would be safe and potentially effective in use as a probiotic. We propose to test this in vivo in future work.

**Competing interests** None declared.

**PWE-231** MRI IS CORRELATED TO FACIAL CALPROTECTIN LEVEL IN THE EVALUATION OF SMALL BOWEL AND COLONIC CROHN’S DISEASE

doi:10.1136/gutjnl-2012-302514d.231

1 J Makanyanga,* 2D Pendse, 2E Atkins, 1A Menys, 3S Bloom, 3S McCartney, 2Punwani, 2S Halligan, 2T Taylor. 1Centre for Medical Imaging, University College London, London, UK; 2Department of Specialist Radiology, University College London Hospitals, London, UK; 3Department of Gastroenterology, University College London Hospitals, London, UK

**Introduction** Crohn’s disease management requires knowledge of overall disease burden. A new MRI score of Crohn’s disease activity was tested against reference standards of global activity—Harvey Bradshaw index (HBI) and faecal calprotectin.

**Methods** 34 patients (15 male) median age 33 (range 17–78) years with known or suspected Crohn’s disease underwent MR enterography (axial/coronal HASTE, TrueFisp and post gadolinium coronal VIBE/THRIVE at 1.5T (n=24) or 3T (n=10)). Same day HBI questionnaire and faecal calprotectin were measured. Two observers qualitatively graded bowel wall thickness, mural T2 signal, mesenteric oedema, T1 enhancement and colonic hastral loss from 0 (normal) to 3 (most abnormal) for the jejunum, proximal ileum, terminal ileum and colon (six segments). Each individual small bowel and colonic segmental score was multiplied according to the length of disease in that segment (0–5 cm×1, 6–15 cm×1.5, and ≥16 cm×2). For each of lymphadenopathy, comb sign, abscesses and fistulae a score of 5 was added if present. The relationship between MRI score, calprotectin and HBI was evaluated using Kendall’s rank correlation.

**Results** The mean MRI activity score was 15 (range 0–61.5) and was significantly correlated with calprotectin, Kendall’s tau b=0.42, p=0.009, not with HBI, Kendall’s tau b=0.006, p=1.

**Conclusion** Global Crohn’s disease activity measured using a qualitative MRI score is correlated to the faecal calprotectin level. MRI is useful for the global assessment of Crohn’s disease activity.

**Competing interests** None declared.

**PWE-232** ADAMDEC1: A NOVEL MOLECULE IN INFLAMMATION AND BOWEL DISEASE

doi:10.1136/gutjnl-2012-302514d.232

1 R O’Shea,* 1T S Chew, 1G Sewell, 1S Bloom, 1A Smith, 1A Segal. 1Department of Medicine, University College London, London, UK; 2Department of Gastroenterology, University College London, London, UK

**Introduction** Innate immunity is attenuated in patients with Crohn’s disease (CD) with impaired neutrophil recruitment to skin and bowel, delayed clearance of *Escherichia coli* from the skin, and impaired secretion of pro-inflammatory cytokines from macrophages (Marks et al, 2006; Smith et al, 2009). The primary defect of acute inflammation results in failure to eradicate bacterial flora entering the bowel wall leading to the chronic granulomatous inflammation characteristic of CD. Microarray analysis of peripheral blood monocyte derived macrophage mRNA expression, confirmed by qPCR, revealed that ADAMDEC1 (ADAM like Decysin1) was up-expressed in 10% (6/60) of CD patients. ADAMDEC1, a Metalloprotease and Decysin, is part of a family of proteins involved in wound healing and tissue repair, and is almost exclusively expressed in macrophages, dendritic cells and the gastrointestinal tract. To determine the role of this protein we examined *E coli* induced inflammation and Dextran Sodium Sulphate (DSS) colitis in the Adamdec1 knockout (KO) mouse.

**Methods** In an acute colitis model, Adamdec1 KO mice were exposed to 2% DSS for 7 days. Controls, wild type (WT) litter mates, were age, weight and sex matched (n=11 per group). Clinical colitis scores (weight loss, PR blood, loose stool) were recorded daily. Histology was obtained from small and large bowels. For bacterial inflammation, 5×10⁹ heat killed *E coli* (HkEc) were injected subcutaneously (SC) into two sites on the backs of KO and WT mice (n=5 per group). Mice were weighed, injection sites inspected for ulceration and subcutaneous inflammatory nodules measured, daily. Injection sites were excited at different time points for histology and identification of infiltrating cells by FACS.

**Results** Adamdec1 KO mice were more susceptible to DSS colitis. They demonstrated higher clinical colitis scores with an earlier and more dramatic weight loss (p<0.01). A more florid inflammatory response was seen on histology. In response to a subcutaneous injection of *E coli*, Adamdec1 KO mice had significantly smaller inflammatory nodules and less ulceration at the injection sites after 48–72 h, compared with WT mice (p<0.001).

**Conclusion** Mice lacking Adamdec1 develop a phenotype that closely mirrors that observed in patients with CD, an attenuated and delayed *E coli* induced acute inflammatory and an increased susceptibility to bowel inflammation. These results suggest ADAMDEC1 plays an important role in the acute inflammatory response to bacteria and has a protective role within the intestine, reduced levels may have a pivotal role in the development and persistence of CD.

**Competing interests** None declared.

**PWE-233** SINGLE CENTRE COMPARISON OF MORTALITY, HOSPITAL RECORDED SERIOUS ADVERSE EVENTS (SAE) AND PRIMARY CARE RECORDED OPPORTUNISTIC INFECTIONS (OI) IN IBD PATIENTS TREATED WITH ANTI-TNF COMPARED TO THIOPURINES ALONE

doi:10.1136/gutjnl-2012-302514d.233

1O Waters,* 1M Saunders, 2M Bulsara, 1T Ahmad. 1Department of Gastroenterology, Royal Devon & Exeter Hospital Foundation Trust, Exeter, UK; 2Department of Biostatistics, University of Notre Dame, Fremantle, Australia

**Introduction** The safety profile of anti-TNF therapy in IBD has been examined in previous case series, however these have been in tertiary centres, have not included a control cohort, or review of primary care records. We aimed to review SAE including primary care recorded OI, in patients treated with anti-TNF compared to a thiopurine alone.

**Methods** We studied two IBD cohorts: Cohort 1—All 212 anti-TNF treated patients between 1999 and 2010. Cohort 2—220 responders to an invitation sent to 365 patients treated with thiopurines only. A review of primary and secondary care records was conducted. A primary care OI was defined as any infection diagnosed or treated in primary care. Statistical analysis was performed using Stata V12